Menu
← Oncology Approval Tracker
FDA DECISION ·
Oziltus
denosumab-mobz · Amneal Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Xgeva biosimilar for preventing skeletal complications in multiple myeloma or solid tumor bone metastases, treating giant cell tumor of bone in eligible adults and skeletally mature adolescents, and treating malignancy-related hypercalcemia refractory to bisphosphonates.
LAMPGEN ANALYSIS
Why it matters
This oncology-dose denosumab approval adds a biosimilar option for the labeled Xgeva uses.
What research teams should watch
Keep the oncology-dose product and endocrine bone loss product separate in inventory and preadministration checks.
PRIMARY RECORDS